TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26340540
Drug: Zephyr® EBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zephyr® EBV treatment in upper lobe (n=45)
Study: 26340540
Drug: Zephyr® EBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zephyr® EBV treatment in lower lobe (n=15)
Study: 24042256
Drug: Aspirin (81-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81-100 mg daily)
Study: 19848195
Drug: Qingxuan Tiaoya
Normalized name: SILICON DIOXIDE 14 g in 100 g / .ALPHA.-TOCOPHEROL ACETATE 0.1 g in 100 g / SODIUM PYROPHOSPHATE 0.5 g in 100 g DENTAL PASTE, DENTIFRICE [Mastikis Qingxin Care Mastic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingxuan Tiaoya Recipe (QXTYR) + perindopril tablet
Study: 19848195
Drug: Simulator of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulator of QXTYR + perindopril tablet
Study: 17563125
Drug: Ebastine 10
Normalized name: ebastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10 mg FDT
Study: 10091410
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Peripheral blood stem cells (PBSC) collected after induction and consolidation chemotherapy, followed by ABSCT immediately thereafter.
Study: 10091410
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: PBSC collected after consolidation alone, followed by intermediate dose cytarabine (Ara‐C 1 g/m2/12 h x3 days) and mitoxantrone (12 mg/m2/d x3 days) as early intensification before ABSCT.
Study: 7844085
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of salbutamol plus beclomethasone
Study: 624427
Drug: Low-dose cortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cortisone
Study: 30587521
Drug: Linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleic acid solution
Study: 30587521
Drug: Sweet (sucrose)
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sweet (sucrose) solution
Study: 30587521
Drug: Salty (NaCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salty (NaCl) solution
Study: 30587521
Drug: Five FFA
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five FFA solutions
Study: 26771291
Drug: Citalopram (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (8 weeks treatment)
Study: 22115379
Drug: Solution Focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution Focused Therapy (SFT)
Study: 16892911
Drug: Vaccine efficacy
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine efficacy against infection and disease
Study: 15572812
Drug: Terbutaline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (250 mcg, 3 puffs)
Study: 15572812
Drug: Salbutamol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (100 mcg, 3 puffs)
Study: 29253068
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/day for 1 year
Study: 24955550
Drug: Saffron aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron aqueous extract (SAE) 30 mg daily
Study: 24955550
Drug: Crocin 30
Normalized name: CROCIN
DrugBank: Crocin (DB11874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin 30 mg daily
Study: 15914936
Drug: β-blockers, angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockers, angiotensin-converting enzyme inhibitors, aldosterone antagonists, and statins
Study: 7888013
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (600 mg)
Study: 7888013
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 before normal saline infusion
Study: 1943180
Drug: Herbomineral formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbomineral formulation (Articulin‐F)
Study: 22395893
Drug: Subthreshold laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subthreshold laser treatment (STLT)
Study: 22395893
Drug: Threshold laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold laser treatment (TLT)
Study: 12150481
Drug: Streptomycin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptomycin 30 mg/kg
Study: 12150481
Drug: Streptomycin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptomycin 15 mg/kg
Study: 12150481
Drug: Streptomycin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptomycin 7.5 mg/kg
Study: 12150481
Drug: Paromomycin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin 7.5 mg/kg
Study: 1330386
Drug: Lisinopril 10-20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10-20 mg once daily
Study: 2869615
Drug: Propranolol in
Normalized name: propranolol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol in a daily dose of 180 to 240 mg
Study: 29071875
Drug: Oral-appliance plus
Normalized name: Interceptor Plus Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-appliance plus tadalafil (10 mg daily for 3 months)
Study: 29071875
Drug: Oral-appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-appliance
Study: 29071875
Drug: Tadalafil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (10 mg daily for 3 months)
Study: 25772743
Drug: Next.Step e-therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Next.Step e-therapeutic platform accessed during 24 weeks in addition to standard treatment program
Study: 22715808
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of DHA
Study: 21521341
Drug: Oral DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral DHEA 50 mg/day
Study: 16581113
Drug: Intralesional interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional interferon-alpha 2b combined with oral vitamin E
Study: 16581113
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin E alone
Study: 12701068
Drug: Mixed meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed meals containing 15,000 retinol equivalents (RE) of vitamin A (as retinyl palmitate) with 40 g of fat (butter)
Study: 12701068
Drug: Mixed meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed meals containing 15,000 retinol equivalents (RE) of vitamin A (as retinyl palmitate) with 40 g of fat (olive oil)
Study: 12701068
Drug: Mixed meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed meals containing 15,000 retinol equivalents (RE) of vitamin A (as retinyl palmitate) with 40 g of fat (sunflower oil)
Study: 7963281
Drug: Home-based program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based program with music listening stress reduction techniques at weekly home visits by a music therapist
Study: 7963281
Drug: Self-administered program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered program with music listening stress reduction techniques and moderate therapist intervention (weekly telephone call)
Study: 3297718
Drug: Ambroxol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (120 mg/day) for 40 days after chemotherapy course
Study: 25556490
Drug: Fluvoxamine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine combined with oxycodone prolonged-release tablets
Study: 25556490
Drug: Oxycodone prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone prolonged-release tablets alone (Control)
Study: 17884832
Drug: Fixed-dose paediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose paediatric granule co-formulation (10-20 kg body weight)
Study: 17884832
Drug: Free-dose co-blister
Normalized name: Blister Armour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free-dose co-blister tablet formulation of artesunate-mefloquine (>20-40 kg body weight)
Study: 3353893
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (3.2 g eicosapentaenoic acid and 2.2 g docosahexaenoic acid daily)
Study: 31227535
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral probiotic combination of Lactobacillus rhamnosus, GG (LGG) and Bifidobacterium animalis subsp. lactis, BB‐12 (BB‐12)
Study: 28463747
Drug: CBT-SP (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-SP (Cognitive Behaviour Therapy with Support Person)
Study: 28463747
Drug: CBT-A (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-A (Cognitive Behaviour Therapy Alone)
Study: 23015541
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (65 mg)
Study: 21464363
Drug: High alcohol
Normalized name: High alcohol lager
Approvals — FDA: no, EMA: no, PMDA: no
Description: High alcohol dose (0.8 g/kg)
Study: 9457454
Drug: Topical tetracaine
Normalized name: tetracaine Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracaine 1%
Study: 9457454
Drug: Topical bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bupivacaine 0.75%
Study: 2514474
Drug: Oxamniquine 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxamniquine 20, 30 or 40 mg/kg
Study: 2514474
Drug: Praziquantel 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 20, 30 or 40 mg/kg
Study: 2514474
Drug: Praziquantel 30
Normalized name: praziquantel 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 30 or 40 mg/kg
Study: 2514474
Drug: Higher dosages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosages of both drugs
Study: 2514474
Drug: Population chemotherapy
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Population chemotherapy
Study: 2514474
Drug: Lower treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower treatment schedules
Study: 1055315
Drug: Clonidine alone
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine alone or in conjunction with diuretics and other hypertensive drugs
Study: 24663814
Drug: Xylitol chewing
Normalized name: xylitol Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol chewing gum (6 g/day for 5 weeks)
Study: 23158806
Drug: AG200-15 Agile
Normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG200-15 Agile Patch (AP) under normal conditions
Study: 23158806
Drug: AG200-15 Agile
Normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG200-15 Agile Patch (AP) under cool water conditions
Study: 23158806
Drug: AG200-15 Agile
Normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG200-15 Agile Patch (AP) under all conditions
Study: 11254838
Drug: Fluid challenge
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid challenge (2-L) in intraoperative patients
Study: 7913934
Drug: Adjunctive antithyroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antithyroid drugs (MMI and L-T4)
Study: 7913934
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (RAI and adjunctive antithyroid drugs)
Study: 2847600
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg nedocromil sodium
Study: 8386917
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nedocromil sodium
Study: 2847600
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg nedocromil sodium
Study: 30471715
Drug: rhIGF-1/rhIGFBP-3 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF-1/rhIGFBP-3 (250 µg/kg/24 hours, continuous intravenous infusion from <24 hours of birth to postmenstrual age 296/7 weeks)
Study: 22142523
Drug: Greater occipital
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater occipital nerve block with steroid
Study: 19737849
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor prescribed to be taken as needed for relief of epigastric pain
Study: 16490093
Drug: Caudal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal morphine (30 microg.kg(‐1) in 1 ml.kg(‐1) saline)
Study: 11345025
Drug: Ukrain (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ukrain (10 mg every second day, repeated 10 times) and vitamin C (5.4 g every second day, repeated 10 times)
Study: 11345025
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (vitamin C (5.4 g every second day, repeated 10 times) and normal saline (10 ml))
Study: 9192511
Drug: Intermittent cyclical
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cyclical etidronate (400 mg/day for 14 days) followed by cyclical calcitriol therapy (0.25 microg twice daily)
Study: 9192511
Drug: Calcitriol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.25 microg/day) in combination with 100 IU intranasal salmon calcitonin every other day
Study: 3515920
Drug: Flurbiprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (200 to 300 mg total daily dosage, four times daily)
Study: 15231982
Drug: Once-Daily Dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-Daily Dosing (ODD) of aminoglycosides
Study: 15231982
Drug: Multiple Daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Daily Dosing (MDD) of aminoglycosides
Study: 9578507
Drug: Daily s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily s.c. injections of 0.9 mg/m2 hGH
Study: 7715582
Drug: Antioxidant treatment
Normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant treatment with selenium
Study: 7715582
Drug: Scavenger treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scavenger treatment
Study: 619607
Drug: Diphenylhydantoin (DPH)
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenylhydantoin (DPH) at a concentration of 20 microgram/ml
Study: 619607
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution of orange juice
Study: 30701613
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (380 mg intramuscularly injected every four weeks)
Study: 30701613
Drug: Buprenorphine-naloxone (flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-naloxone (flexible 4-16 mg sublingual doses daily)
Study: 30701613
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from buprenorphine-naloxone to extended-release naltrexone
Study: 26471464
Drug: Bexident Post
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexident Post (BP) gel, used three times daily after tooth extraction.
Study: 26471464
Drug: Bicarbonate (BC)
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate (BC) oral rinse, used three times daily after tooth extraction.
Study: 22733001
Drug: Wild blueberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wild blueberry drink (25 g freeze-dried powder providing 375 mg of ACNs)
Study: 19923636
Drug: Oral solutions
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solutions of doxylamine succinate and pyridoxine hydrochloride
Study: 7549079
Drug: Aspirin, beta-blockers,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, beta-blockers, converting enzyme inhibitors
Study: 7549079
Drug: Newer antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer antithrombotic and antiplatelet agents (hirudin, glycoprotein IIb/IIIa receptor antagonists)
Study: 6975823
Drug: Trimethoprim (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (300 mg once a day for seven days)
Study: 6975823
Drug: Co-trimoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (160 mg trimethoprim, 800 mg sulphamethoxazole, two tablets twice a day for seven days)
Study: 31766743
Drug: l-Carnitine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Carnitine administration (200 mg/kg/day)
Study: 31766743
Drug: l-Carnitine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Carnitine administration (50-100 mg/kg/day)
Study: 31766743
Drug: l-Carnitine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Carnitine administration
Study: 31766743
Drug: l-Carnitine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Carnitine administration in ASD associated with genetic disorders
Study: 21546089
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg VEGF Trap‐Eye every 4 weeks
Study: 21546089
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg VEGF Trap‐Eye every 4 weeks
Study: 21546089
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg VEGF Trap‐Eye for 3 initial monthly doses and then every 8 weeks
Study: 21546089
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg VEGF Trap‐Eye for 3 initial monthly doses and then on an as‐needed (PRN) basis
Study: 17278206
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation and anti-H pylori therapy
Study: 15083479
Drug: Bayesian, counterfactual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayesian, counterfactual approach using data augmentation (DA) algorithm
Study: 11597814
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (HFRT) - 59.4 Gy in 54 1.1-Gy twice daily fractions
Study: 11597814
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated radiotherapy (CFRT) - 50.4 Gy in 28 1.8-Gy daily fractions
Study: 9588436
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of donepezil hydrochloride
Study: 9588436
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of donepezil hydrochloride
Study: 7985937
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (standard therapy regimen)
Study: 7985937
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (standard therapy regimen plus plasmapheresis)
Study: 7985937
Drug: Protocol C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C (standard therapy regimen plus pulse methylprednisolone)
Study: 2574553
Drug: terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 60 mg every 12 hours
Study: 2574553
Drug: terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 120 mg each day
Study: 31312144
Drug: Oral Contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptives (30 μg ethinyl estradiol)
Study: 31312144
Drug: Oral Contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptives (20 μg ethinyl estradiol)
Study: 24171791
Drug: Intraocular irrigating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraocular irrigating solution
Study: 16443353
Drug: Ciclesonide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide (80 or 160 microg daily)
Study: 16443353
Drug: Fluticasone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (100 microg twice daily)
Study: 16443353
Drug: Ciclesonide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide (160 microg daily)
Study: 12960650
Drug: Erythromycin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (1.5 mg/kg)
Study: 1831005
Drug: Dermal pretreatment
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermal pretreatment with 0.5% hydrocortisone cream
Study: 1831005
Drug: Dermal pretreatment
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermal pretreatment with magnesium-aluminum hydroxide suspension
Study: 1831005
Drug: Transdermal patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch alone
Study: 1831005
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (hydrocortisone, magnesium-aluminum hydroxide, patch alone)
Study: 7049351
Drug: Ascorbic acid,
Normalized name: ASCORBIC ACID, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascorbic acid, 3 g/day
Study: 19378912
Drug: Daily supine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supine cycle exercise (Exercise group; N = 14)
Study: 17387462
Drug: Ximelagatran co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran co-administered with azithromycin
Study: 17387462
Drug: Ximelagatran co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran co-administered with cefuroxime
Study: 17387462
Drug: Ximelagatran co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran co-administered with amoxicillin, doxycycline, or ciprofloxacin
Study: 9049513
Drug: Nisoldipine coat-core
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine coat-core (nisoldipine-CC)
Study: 8396103
Drug: Azithromycin, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, single daily dose of 10 mg/kg (maximum 500 mg) for three days (n = 46)